COVID-19 affects power demand
COVID-19 affects power demand

COVID-19 affects power demand

DSIJ Intelligence Article rating: 5.0

The outbreak of Coronavirus has impacted various sectors globally and domestically. The current lockdown that has been implemented pan India has forced a cut in power demand.

Government shuts toll collection amid countrywide lockdown
Government shuts toll collection amid countrywide lockdown

Government shuts toll collection amid countrywide lockdown

Amir Shaikh Article rating: 5.0

In light of the recent outbreak of COVID-19, Ministry of Road Transport & Highways (MoRTH) has asked National Highways Authority of India (NHAI) to suspend toll collection at all toll plaza across India 

Indices head for strong weekly gain; closes higher
Indices head for strong weekly gain; closes higher

Indices head for strong weekly gain; closes higher

Pratik Shastri Article rating: 3.7

The indices were topped by IndusInd Bank, which gained as much as 45 per cent intra-day. The stock has seen a sharp sell-off since the start of the month due to the reports of regulatory issues in the numbers.

NIIT to help organisations in minimising COVID-19 impact
NIIT to help organisations in minimising COVID-19 impact

NIIT to help organisations in minimising COVID-19 impact

DSIJ Intelligence Article rating: 5.0

COVID-19 pandemic is an ongoing global crisis. Many companies are trying to assist the patients of the disease, their families and anyone else, who is being adversely affected by this tragic outbreak.

Caplin Point shares hit upper-circuit post USFDA nod
Caplin Point shares hit upper-circuit post USFDA nod

Caplin Point shares hit upper-circuit post USFDA nod

DSIJ Intelligence Article rating: 4.6

The share price of Caplin Point was trading in green on Thursday after the company got approval from the United States Food and Drug Administration (USFDA) for its Verapamil Hydrochloride Injection USP.

Cipla receives final USFDA approval for Esomeprazole
Cipla receives final USFDA approval for Esomeprazole

Cipla receives final USFDA approval for Esomeprazole

DSIJ Intelligence Article rating: 3.0

Mumbai-based drug major, Cipla announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Esomeprazole for oral suspension 10 mg, 20 mg and 40 mg.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 3.5

The market opened in the geen on March 26, 2020, overall volumes in futures & options currently stand at 1.37 crore contracts with a turnover of Rs. 6,81,476.99 crore.

Strides Pharma gets EIR for Bengaluru facility from USFDA
Strides Pharma gets EIR for Bengaluru facility from USFDA

Strides Pharma gets EIR for Bengaluru facility from USFDA

Apurva Joshi Article rating: 5.0

Strides Pharma Science Limited has informed the bourses that its flagship facility (KRS Gardens) in Bengaluru has received an establishment inspection report (EIR) thereby, confirming the successful closure of the inspections.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

DSIJ Intelligence Article rating: 5.0

The market opened in the green on March 26, 2020, overall volumes in futures & options currently stand at 1.37 crore contracts with a turnover of Rs. 6,81,476.99

Stocks close to their 52-week high
Stocks close to their 52-week high

Stocks close to their 52-week high

DSIJ Intelligence Article rating: 3.8

The market opened in the green on March 26, 2020. The previous trading session witnessed the Sensex going up by 7 percent to end at 28,535.27 and the Nifty was up by 6.62 percent to close at 8,317.38.

RSS
First31143115311631173119312131223123Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR